Is early loss of minimal luminal diameter after successful PTCA prevented by c7E3 IIb/IIIa antiplatelet antibody?

被引：0
|
作者：
Leon, MN [1 ]
Gold, HK [1 ]
Mahdi, NA [1 ]
Harrell, L [1 ]
Rodriguez, A [1 ]
Palacios, IF [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 1998年 / 31卷 / 02期
关键词：
D O I：
10.1016/S0735-1097(97)83945-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：55A / 55A
页数：1
相关论文
共 49 条
  • [31] INHIBITION OF PLATELET-AGGREGATION BY ANTIPLATELET GP-IIB-IIIA (7E3) FAB MURINE MONOCLONAL-ANTIBODY - RELATIONSHIP TO DOSE
    BHATTACHARYA, S
    MACKIE, I
    MACHIN, S
    LEESE, P
    SCHAIBLE, T
    JORDAN, R
    SMITH, C
    BERGER, H
    LAHIRI, A
    ARTERIOSCLEROSIS, 1990, 10 (05): : A910 - A910
  • [32] Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro
    Koestenberger, M
    Gallistl, S
    Cvirn, G
    Roschitz, B
    Muntean, W
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (05) : 425 - 432
  • [33] SHEAR-INDUCED PLATELET-AGGREGATION IS INHIBITED BY IN-VIVO INFUSION OF AN ANTI-GLYCOPROTEIN IIB/IIIA ANTIBODY FRAGMENT, C7E3 FAB, IN PATIENTS UNDERGOING CORONARY ANGIOPLASTY
    KONSTANTOPOULOS, K
    KAMAT, SG
    SCHAFER, AI
    BANEZ, EI
    JORDAN, R
    KLEIMAN, NS
    HELLUMS, JD
    CIRCULATION, 1995, 91 (05) : 1427 - 1431
  • [34] XV454, a novel nonpeptide small-molecule platelet GIIb/IIIa antagonist with comparable platelet αIIbβ3-binding kinetics to c7E3
    Mousa, SA
    Forsythe, M
    Bozarth, J
    Youssef, A
    Wityak, J
    Olson, R
    Sielecki, T
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 32 (05) : 736 - 744
  • [35] THE EFFECT OF THROMBIN INHIBITION AND ANTIPLATELET MEMBRANE GLYCOPROTEIN-IIB/IIIA MONOCLONAL ANTIBODY-7E3 ON PLATELET DEPOSITION IN A NEW EXVIVO ANGIOPLASTY MODEL
    KAPLAN, AV
    LEUNG, LLK
    LEUNG, WH
    FISCHELL, TA
    ARTERIOSCLEROSIS, 1990, 10 (05): : A945 - A945
  • [36] PACIFICATION OF CORONARY-ARTERY THROMBOSIS AFTER DEEP ARTERIAL INJURY BY THE ANTIPLATETLET GLYCOPROTEIN IIB/IIIA 7E3 ANTIBODY
    WALSH, DG
    BATES, ER
    MU, DX
    LUCCHESI, BR
    CLINICAL RESEARCH, 1991, 39 (02): : A197 - A197
  • [37] Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization
    Lincoff, AM
    Tcheng, JE
    Califf, RM
    Bass, T
    Popma, JJ
    Teirstein, PS
    Kleiman, NS
    Hattel, LJ
    Anderson, HV
    Ferguson, JJ
    Cabot, CF
    Anderson, KM
    Berdan, LG
    Musco, MH
    Weisman, HF
    Topol, EJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (03): : 286 - 291
  • [38] Marked enhancement of clinical efficacy of platelet GP IIb/IIIa blockade with c7E3 fab (Abciximab) linked to reduction in bleeding complications: Outcome in the EPILOG and EPIC trials
    Lincoff, AM
    Tcheng, JE
    Miller, DP
    Booth, JE
    Montague, EA
    Topol, EJ
    CIRCULATION, 1996, 94 (08) : 2185 - 2185
  • [39] Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha(IIb)beta(3) (GPIIb/IIIa) antagonists, c7E3 and DMP728
    Tsao, PW
    Forsythe, MS
    Mousa, SA
    THROMBOSIS RESEARCH, 1997, 88 (02) : 137 - 146
  • [40] XV454, a novel non-peptide antiplatelet agent with comparable platelet alpha IIb beta 3 binding kinetics to c7E3 and long lasting antiplatelet efficacy after single intravenous or oral administration in non-human primates
    Mousa, SA
    Bozarth, JM
    Forsythe, MS
    Thoolen, M
    Reilly, TM
    Wityak, J
    Olson, RE
    Sielecki, TM
    CIRCULATION, 1997, 96 (08) : 928 - 928
12345